Health Tech Lunch - Thomas Vetterli - “Facilitating the adoption of liquid biopsy with the development of computational methods focused on clinical actionability”
![Discover the Institute of Computer Science at HES-SO Valais-Wallis, a leader in software engineering and digital transformation. Our team of over 100 specialists and researchers enhances business competitiveness and quality of life through applied research projects. Explore our research areas in eHealth, energy and digitalization, and digital industry. Join our community committed to technological innovation.](/media/image/20/xlarge_2_1/header-iig-e-1378.jpg?3a3f65fa325395fb10883eef3935d9bb)
The Axe Santé is organising a Health Tech Lunch on Wednesday, June 5th from 12:00 to 13:00 at Swiss Digital Center in Sierre (room Maïa).
Biography : Thomas Vetterli graduated in 2017 at the EPFL where he obtained his Master of Science with a particular focus on biomedical engineering and data science for life sciences. During his Master's he spent 6 months at Columbia University working on deep learning methods to mine insights from imaging data and learn diagnostically relevant features. Thomas then moved to San Francisco where, as a Senior Machine Learning at Freenome and Berkeley Lights, he participated and led the development of machine learning and bioinformatic platforms and models for early cancer detection and single cell automation. Thomas is now the Director of Machine Learning and Bioinformatics at Hedera Dx - an oncology company specialising in liquid biopsy testing. In his role, he leads a team in developing NGS tumor monitoring pipelines for liquid biopsies.
Abstract : Liquid biopsies have emerged as a versatile technology with numerous applications in routine cancer care - from tumour profiling to minimal residual disease testing to early detection. HederaDx is an oncology company specialising in liquid biopsy testing. The company develops targeted sequencing kits as well as bioinformatic methods that have a focus on detecting clinically actionable variants to help with the prescription of targeted therapies. In this presentation we will review the clinical need of targeted therapies as well as the design strategies behind our kits and methods to ensure that they can be used in routine cancer diagnostics.
Programme :
Registration : https://doodle.com/meeting/participate/id/dwnvyXRb